Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid s Q1 Revenues Grow 3 Percent As Net Loss Widens

NEW YORK, May 5 (GenomeWeb News) – Cepheid announced yesterday that its Q1 revenues increased 3 percent to $20.2 million from $19.6 million during the year-ago period, while its net loss grew 9.3 percent to $6.7 million from $3.5 million during the first quarter of 2005. Research and development costs grew 2.9 percent to $5.8 million from $4.5 million during the first quarter of 2005. As of March 31, Cepheid had $59.7 million in cash and cash equivalents.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more